

TUTOGEN MEDICAL INC
Form 10-Q
August 14, 2007

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.

For the period ended June 30, 2007

Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934.

For the transition period from _____ to _____.

COMMISSION FILE NUMBER: 0-16128

TUTOGEN MEDICAL, INC.

(Exact name of registrant as specified in its charter)

FLORIDA
(State of Incorporation)

59-3100165
(IRS Employer Identification Number)

13709 Progress Boulevard, Box 19, Alachua, Florida 32615
(Address of Principal Executive Offices)

Registrant's telephone number, including area code (386) 462-0402

Indicate by check mark whether the registrant: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Act).

Large accelerated filer Accelerated filer Non-accelerated filer

As of July 31, 2007 there were 19,094,571 shares outstanding of the issuer's Common Stock, par value \$.01 per share.

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

INDEX

| PART I. | Page No. |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| ITEM 1. Financial Statements. | |
| Unaudited - Condensed Consolidated Balance Sheets - June 30, 2007 and September 30, 2006. | 1 |
| Unaudited - Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) for the three and nine-months ended June 30, 2007 and 2006. | 2 |
| Unaudited - Condensed Consolidated Statements of Cash Flows for the nine-months ended June 30, 2007 and 2006. | 3 |
| Unaudited - Condensed Consolidated Statement of Shareholders' Equity for the nine-months ended June 30, 2007. | 4 |
| Unaudited - Notes to Condensed Consolidated Financial Statements. | 5 |
| ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. | 13 |
| ITEM 3. Quantitative and Qualitative Disclosures about Market Risk | 19 |
| ITEM 4. Controls and Procedures. | 19 |
| PART II. | |
| ITEM 1. Legal Proceedings | 20 |
| ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds | 20 |
| ITEM 3. Defaults Upon Senior Securities | 20 |
| ITEM 4. Submission of Matters to a Vote of Security- Holders | 20 |
| ITEM 5. Other Information | 20 |
| ITEM 6. Exhibits | 21 |
| SIGNATURES | 21 |

PART I. FINANCIAL INFORMATION**ITEM 1. FINANCIAL STATEMENTS.**

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT FOR SHARE DATA)
(UNAUDITED)

| | June 30 2007 | September 30 2006 |
|----------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------|
| ASSETS | | |
| Current Assets | | |
| Cash and cash equivalents | \$ 11,844 | \$ 3,463 |
| Accounts receivable - net of allowance for doubtful accounts of \$642 at June 2007 and \$483 at September 2006 | 6,792 | 6,202 |
| Inventories - net | 18,108 | 12,678 |
| Deferred tax asset | 2,908 | 471 |
| Prepays and other current assets | 1,546 | 1,436 |
| | 41,198 | 24,250 |
| Property, plant, and equipment - net | 14,015 | 12,940 |
| Other assets | 155 | 424 |
| Deferred tax asset | 3,464 | 1,303 |
| TOTAL ASSETS | \$ 58,832 | \$ 38,917 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | |
| Current Liabilities | | |
| Accounts payable | \$ 1,743 | \$ 1,346 |
| Accrued expenses and other current liabilities | 3,794 | 4,314 |
| Accrued commissions | 2,500 | 1,918 |
| Short-term borrowings | 1,979 | 5,783 |
| Current portion of deferred distribution fees | 1,680 | 1,577 |
| Current portion of long-term debt | 1,337 | 1,097 |
| | 13,033 | 16,035 |
| Noncurrent Liabilities | | |
| Other noncurrent liabilities | 2,887 | 3,988 |
| Long-term debt | 2,994 | 3,673 |
| Total Liabilities | 18,914 | 23,696 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-Q

Shareholders' Equity :

| | | |
|---------------------------------------------------------------------------------------------------------------|----------|----------|
| Common stock, \$0.01 par value, 30,000,000 authorized; 19,090,971 and 16,197,235 issued and outstanding | 191 | 162 |
| Additional paid-in capital | 54,603 | 37,751 |
| Accumulated other comprehensive income | 3,012 | 2,393 |
| Accumulated deficit | (17,888) | (25,085) |
| Total shareholders' equity | 39,918 | 15,221 |

**TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY**

\$ 58,832 \$ 38,917

See accompanying Notes to Consolidated Financial Statements

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME
(LOSS)
(IN THOUSANDS EXCEPT PER SHARE DATA)
(UNAUDITED)

| | Three Months Ended June 30 | | Nine Months Ended June 30 | |
|-----------------------------------------------------------|---------------------------------------|-------------|--------------------------------------|-------------|
| | 2007 | 2006 | 2007 | 2006 |
| Revenue | \$ 14,163 | \$ 10,000 | \$ 38,643 | \$ 27,149 |
| Cost of revenue | 5,737 | 5,189 | 15,430 | 12,476 |
| Gross profit | 8,426 | 4,811 | 23,213 | 14,673 |
| Operating Expenses | | | | |
| General and administrative | 2,013 | 2,273 | 6,315 | 5,629 |
| Distribution and marketing | 4,184 | 3,332 | 11,589 | 9,352 |
| Research and development | 566 | 452 | 1,562 | 1,319 |
| Total Operating Expenses | 6,763 | 6,057 | 19,466 | 16,300 |
| Operating income (loss) | 1,663 | (1,246) | 3,747 | (1,627) |
| Foreign exchange loss | (21) | (233) | (83) | (261) |
| Interest income | 121 | 12 | 193 | 42 |
| Interest expense | (372) | (75) | (1,016) | (53) |
| | (272) | (296) | (906) | (272) |
| Income (loss) before taxes | 1,391 | (1,542) | 2,841 | (1,899) |
| Income tax benefit | (4,516) | (413) | (4,356) | (711) |
| Net income (loss) | \$ 5,907 | \$ (1,129) | \$ 7,197 | \$ (1,188) |
| Other comprehensive income | | | | |
| Foreign currency translation adjustments | 108 | 377 | 619 | 573 |
| Comprehensive income (loss) | \$ 6,015 | \$ (752) | \$ 7,816 | \$ (615) |
| Average shares outstanding for basic earnings per share | 18,517,927 | 16,058,724 | 17,201,897 | 15,993,936 |
| Basic earnings (loss) per share | \$ 0.32 | \$ (0.07) | \$ 0.42 | \$ (0.07) |
| Average shares outstanding for diluted earnings per share | 19,950,357 | 16,058,724 | 18,730,575 | 15,993,936 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-Q

| | | | | | | | | |
|-----------------------------------|----|------|----|--------|----|------|----|--------|
| Diluted earnings (loss) per share | \$ | 0.30 | \$ | (0.07) | \$ | 0.38 | \$ | (0.07) |
|-----------------------------------|----|------|----|--------|----|------|----|--------|

See accompanying Notes to Consolidated Financial Statements

2

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)

| | Nine Months Ended June 30 | |
|--------------------------------------------------------------------------------------|--------------------------------------|-------------|
| | 2007 | 2006 |
| Cash flows used in operating activities | | |
| Net income (loss) | \$ 7,197 | \$ (1,188) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | |
| Depreciation and amortization | 1,345 | 688 |
| Amortization of deferred distribution fees revenue | (1,012) | (407) |
| Severance costs | - | 437 |
| Amortization of debt discount and debt issuance costs | 206 | - |
| Reserve for bad debt | 164 | - |
| Provision for inventory write-downs | 103 | 741 |
| Share-based compensation | 702 | 303 |
| Deferred income taxes | (4,507) | (693) |
| Changes in assets and liabilities: | | |
| Accounts receivable | (597) | (1,410) |
| Inventories | (5,263) | (3,061) |
| Other assets | 349 | (503) |
| Accounts payable and other accrued expenses | (501) | (183) |
| Accrued commissions | 582 | 171 |
| Deferred distribution fees | 63 | 1,650 |
| Net cash used in operating activities | (1,169) | (3,455) |
| Cash flows used in investing activities | | |
| Deposits on purchase of property and equipment | - | (300) |
| Purchase of property and equipment | (1,779) | (5,280) |
| Net cash used in investing activities | (1,779) | (5,580) |
| Cash flows provided by financing activities | | |
| Proceeds from issuances of common stock | 12,000 | 383 |
| Fees associated with issuance of common stock | (506) | - |
| Exercise of stock options | 1,685 | - |
| Debt and equity issuance costs | (152) | (205) |
| Proceeds from issuance of convertible debt and warrants | - | 3,000 |
| Proceeds from long-term borrowings | 129 | 3,186 |
| Change in short-term borrowings | (1,000) | 2,559 |
| Repayment of long-term debt | (870) | (228) |
| Net cash provided by financing activities | 11,286 | 8,695 |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-Q

| | | | | |
|--------------------------------------------------------------|----|--------|----|-------|
| Effect of exchange rate changes on cash and cash equivalents | | 43 | | 573 |
| Net increase in cash and cash equivalents | | 8,381 | | 233 |
| Cash and cash equivalents at beginning of period | | 3,463 | | 3,562 |
| Cash and equivalents at end of period | \$ | 11,844 | \$ | 3,795 |
| Supplemental cash flow disclosures | | | | |
| Interest paid | \$ | 368 | \$ | 231 |
| Income taxes paid | \$ | 8 | \$ | - |

See accompanying Notes to Consolidated Financial Statements

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
NINE-MONTHS ENDED JUNE 30, 2007
(Unaudited)

(In Thousands, Except for Share Data)

| | Common Stock (\$01 Par) | Additional Paid In Capital | Accumulated Other Comprehensive Income (1) | Accumulated Deficit | Total | Common Shares Issued and Outstanding |
|--------------------------------------------|----------------------------------------|-------------------------------------------|---------------------------------------------------------------|--------------------------------|--------------|-----------------------------------------------------|
| BALANCE, SEPTEMBER 30, 2006 | \$ 162 | \$ 37,751 | \$ 2,393 | \$ (25,085) | \$ 15,221 | 16,197,235 |
| Stock issued on exercise of options | 7 | 1,678 | - | - | 1,685 | 685,200 |
| Stock issued on conversion of debt | 6 | 2,994 | - | - | 3,000 | 582,524 |
| Stock issued for private offering | 16 | 11,478 | - | - | 11,494 | 1,626,012 |
| Share-based compensation | - | 702 | - | - | 702 | - |
| Net income | - | - | - | 7,197 | 7,197 | - |
| Foreign currency translation adjustment | - | - | 619 | - | 619 | - |
| BALANCE, JUNE 30, 2007 | \$ 191 | \$ 54,603 | \$ 3,012 | \$ (17,888) | \$ 39,918 | 19,090,971 |

(1) Represents foreign currency translation adjustments.

See accompanying Notes to Consolidated Financial Statements

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND NINE-MONTH PERIODS ENDED JUNE 30, 2007 AND 2006
(UNAUDITED)
(IN THOUSANDS, EXCEPT FOR SHARE DATA)

1. OPERATIONS AND ORGANIZATION

Tutogen Medical, Inc. with its consolidated subsidiaries (the "Company") processes, manufactures and distributes worldwide, specialty surgical products and performs tissue processing services for neuro, orthopedic, reconstructive and general surgical applications. The Company's core business is processing human donor tissue, utilizing its patented TUTOPLAST(R) process, for distribution to hospitals and surgeons. The Company processes at its two manufacturing facilities in Germany and the United States and distributes its products and services to over 20 countries worldwide.

2. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial reporting. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been made. Operating results for the three and nine-month periods ended June 30, 2007 are not necessarily indicative of the results which may be expected for the fiscal year ending September 30, 2007. The interim financial statements should be read in conjunction with the audited consolidated financial statements of the Company included in the Company's Annual Report on Form 10-K for the year ended September 30, 2006. Certain reclassifications have been made to the prior financial statements to conform to the current presentation, including reclassing certain insurance premium costs previously expensed in cost of revenue to general and administrative expenses, and splitting out the previous balance sheet line item accounts payable and other accrued expenses into separate line items of accounts payable and accrued expenses and other current liabilities.

3. NEW ACCOUNTING PRONOUNCEMENTS

In June 2006, the FASB issued FASB Interpretation ("FIN") No. 48 "*Accounting for Uncertainty in Income Taxes*". This interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS No. 109. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Under this interpretation, the evaluation of a tax position is a two-step process. First, the enterprise determines whether it is more-likely-than-not that a tax position will be sustained upon examination, based on the technical merits of the position. The second step is measuring the benefit to be recorded from tax positions that meet the more-likely-than-not recognition threshold, whereby the enterprise determines the largest amount of tax benefit that is greater than 50 percent likely of being realized upon ultimate settlement, and recognizes that benefit in its financial statements. FIN No. 48 also provides guidance on recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. FIN No. 48 is effective for fiscal years beginning after December 15, 2006. Management has not yet determined the impact this pronouncement will have on the Company's financial statements.

In September 2006, the FASB issued SFAS No. 157, "*Fair Value Measurements*" ("*SFAS No. 157*"). This standard defines fair value, establishes a framework for measuring fair value in accounting principles generally accepted in the United States ("GAAP"), and expands disclosures about fair value measurements. This standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company is currently evaluating the requirements of SFAS No. 157 and has not yet determined the impact on the Company's financial statements.

In September 2006, the SEC staff issued Staff Accounting Bulletin (“SAB”) No. 108, *“Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements”* SAB No. 108 eliminates the diversity of practice surrounding how public companies quantify financial statement misstatements. It establishes an approach that requires quantification of financial statement misstatements based on the effects of the misstatements on each of the Company's financial statements and the related financial statement disclosures. SAB No. 108 must be applied to annual financial statements for their first fiscal year ending after November 15, 2006. Management does not believe the adoption of this standard will have a material impact on the Company's financial statements.

In February 2007, the FASB issued SFAS No. 159, *"The Fair Value Option for Financial Assets and Financial Liabilities"* ("SFAS 159"). SFAS 159 allows entities the option to measure eligible financial instruments at fair value as of specified dates. Such election, which may be applied on an instrument by instrument basis, is typically irrevocable once elected. SFAS 159 is effective for fiscal years beginning after November 15, 2007, and early adoption is allowed under certain circumstances. The Company is in the process of evaluating the financial impact of adopting SFAS 159.

4. STOCK-BASED AWARDS

The Company maintains the 1996 Stock Option Plan (the "Plan") (4,000,000 shares authorized) under which incentive and nonqualified options have been granted to employees, directors and certain key affiliates. Under the Plan, options may be granted at not less than the fair market value on the date of grant. Options may be subject to a vesting schedule and expire four, five or ten years from grant. This plan remains in effect for all options issued during its life.

The Plan was superseded by the Tutogen Medical Inc. Incentive and Non-Statutory Stock Option Plan (the "New Plan") (1,000,000 shares authorized), adopted by the Board of Directors on December 5, 2005 and ratified by the shareholders on March 13, 2006. On March 19, 2007, the shareholders approved increasing the shares authorized under the New Plan from 1,000,000 to 1,500,000. Under the New Plan, options may be granted at not less than the fair market value on the date of grant. Options may be subject to a vesting schedule and expire four, five or ten years from grant.

Effective October 1, 2005, the Company adopted the provisions of SFAS No. 123(R) *"Share Based Payment"* ("SFAS 123(R)"), which establishes the financial accounting and reporting standards for stock-based compensation plans. SFAS No. 123(R) requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors. Under the provisions of SFAS No. 123(R), stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period of the entire award (generally the vesting period of the award).

The Company elected to use the modified prospective transition method as permitted by SFAS No. 123(R) and, therefore, financial results for prior periods have not been restated. Under this transition method, stock-based compensation expense for the three and nine-month periods ended June 30, 2007 includes expense for all equity awards granted prior to, but not yet vested as of October 1, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, *"Accounting for Stock-Based Compensation"* as amended by SFAS No. 148, *"Accounting for Stock-Based Compensation - Transition and Disclosure"*. Since the adoption of SFAS No. 123(R), there have been no changes to the Company's stock compensation plans or modifications to outstanding stock-based awards which would increase the value of any awards outstanding. Compensation expense for all stock-based compensation awards granted subsequent to October 1, 2005 was based on the grant-date fair value determined in accordance with the provisions of SFAS No. 123(R). During the three and nine-month periods ended June 30, 2007, the Company recognized compensation expense of \$129 and \$702, respectively, relating to stock options granted, in addition to the vesting of options outstanding as of October 1, 2005. All such expense was recognized within "General and administrative expense" in the Statement of Income (Loss) and Comprehensive Income (Loss). There were no significant capitalized stock-based compensation costs at June 30, 2007.

The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

| | Three Months Ended June | | Nine Months Ended June 30, | |
|---------------------|-------------------------|------|----------------------------|--------|
| | 30, | | 2007 | 2006 |
| | 2007 | 2006 | 2007 | 2006 |
| Expected volatility | 50.73% | N/A | 51.92% | 50.50% |

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-Q

| | | | | |
|---------------------------------|----|-----|----------|--------------|
| Risk-free interest rate (range) | 5% | N/A | 4.5 - 5% | 3.7 -3.9% |
| Expected term (in years) | 5 | N/A | 5 | 5 |

EXPECTED VOLATILITY. The Company's methodology for computing the expected volatility is based on the Company's historical volatility, taking into account the expected term of the option.

6

EXPECTED TERM. The expected term is based on employee exercise patterns during the Company's history and expectations of employee exercise behavior in the future giving consideration to the contractual terms of the stock-based awards.

RISK-FREE INTEREST RATE. The interest rate used in valuing awards is based on the yield at the time of grant of a U.S. Treasury security with an equivalent remaining term.

DIVIDEND YIELD. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.

PRE-VESTING FORFEITURES. Estimates of pre-vesting option forfeitures of 10% are based on Company experience and industry trends. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

Presented below is a summary of the activity of the Company's stock options for the fiscal year ended September 30, 2006 and the nine-month period ended June 30, 2007, and related transactions for the nine-month period ended:

| | Number of Stock Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term |
|---------------------------------------------|------------------------------------|----------------------------------------------------|--------------------------------------------------------------------|
| Outstanding at September 30, 2005 | 2,481,368 | \$ 2.64 | 5.1 |
| Granted | 125,000 | 3.34 | 10.0 |
| Canceled | (103,225) | 3.84 | - |
| Exercised | (264,275) | 2.45 | - |
| Outstanding at September 30, 2006 | 2,238,868 | \$ 2.65 | 4.8 |
| Granted | 557,500 | 6.72 | 10.0 |
| Canceled | (70,250) | 5.44 | - |
| Exercised | (685,200) | 2.45 | - |
| Outstanding at June 30, 2007 | 2,040,918 | \$ 3.72 | 5.9 |
| Vested at June 30, 2007 | 1,369,418 | \$ 2.88 | 4.4 |
| Vested at June 30, 2007 or expected to vest | 1,836,826 | \$ 3.72 | 5.9 |

The weighted average fair value of options granted during the nine-month period ended June 30, 2007 and the fiscal year ended September 30, 2006 was \$3.40 and \$1.62, respectively. The aggregate intrinsic value of options exercised during the nine-month period ended June 30, 2007 was \$3,200.

Edgar Filing: TUTOGEN MEDICAL INC - Form 10-Q

As of June 30, 2007, there were 875,625 stock options available for grant under the New Plan. The following table provides information about stock options outstanding and exercisable at June 30, 2007:

| Range of Exercise Prices | Options Outstanding | | | | Options Exercisable | | | |
|--------------------------|---------------------|------------------------------------------------------|---------------------------------|---------------------------|---------------------|---------------------------------|---------------------------|--|
| | Options Outstanding | Weighted Average Remaining Contractual Life In Years | Weighted Average Exercise Price | Aggregate Intrinsic Value | Options Exercisable | Weighted Average Exercise Price | Aggregate Intrinsic Value | |
| \$0.94 to \$1.25 | 234,600 | 2.2 | \$ 0.95 | \$ 2,121 | 234,600 | \$ 0.95 | \$ 2,121 | |
| \$1.56 to \$2.22 | 188,568 | 1.6 | 1.69 | 1,565 | 183,568 | 1.68 | 1,526 | |
| \$2.28 to \$3.62 | 828,750 | 6.2 | 2.82 | 5,938 | 653,750 | 2.85 | 4,670 | |
| \$3.95 to \$5.98 | 269,000 | 6.0 | 4.45 | 1,490 | 177,250 | 4.54 | 966 | |
| \$6.01 to \$10.60 | 520,000 | 8.6 | 6.77 | 1,676 | 120,250 | 6.22 | 453 | |
| Totals | 2,040,918 | 5.9 | \$ 3.72 | \$ 12,790 | 1,369,418 | \$ 2.88 | \$ 9,736 | |

As of June 30, 2007, there was \$1,227 of total unrecognized compensation cost related to nonvested stock options that is expected to be recognized over a weighted-average period of 2.17 years.

5. INVENTORIES

Major classes of inventory were as follows:

| | June 30, 2007 | September 30, 2006 |
|-----------------|---------------|--------------------|
| Raw materials | \$ 3,721 | \$ 2,017 |
| Work in process | 7,858 | 5,811 |
| Finished goods | 6,529 | 4,850 |
| | \$ 18,108 | \$ 12,678 |

The increase in inventory from September 30, 2006 to June 30, 2007 was primarily due to higher inventory levels to support increased demand for dental products, the buildup of new products introduced in the spine market and the new markets of hernia repair and breast reconstruction.

6. INCOME TAXES

The Company's third quarter and nine-month period results include a \$4,953 reversal of a previously recorded valuation allowance related to our U.S. operations since we have determined that it is more likely than not that our existing deferred tax assets will be realized. The deferred tax asset balance consists primarily of net operating loss carry forwards, deferred distribution fees and inventory reserves. As of June 30, 2007, the Company has

approximately \$8,837 of federal net operating loss carry forwards expiring beginning in 2012, a \$94 AMT credit carry forward, and a \$21 credit on research and development that will expire in 2013 if unused. The Company also has state net operating loss carry forwards of approximately \$2,168 that will begin to expire in 2025.

As of June 30, 2007, the Company has a corporate net operating loss carry forward for German income tax purposes of approximately \$4,369 (3,242 Euros), and a trade net operating loss carry forward for German income tax purposes of approximately \$2,272 (1,686 Euros), both of which can be carried forward indefinitely. The Company continually reviews the adequacy and necessity of the valuation allowance in accordance with the provisions of SFAS No. 109, *Accounting for Income Taxes*. The Company does not maintain a valuation allowance on its international deferred tax assets, because management believes it is more likely than not that these tax benefits will be realized through the generation of future international taxable income.

Historically, the Company has not recorded deferred income taxes on the undistributed earnings of its foreign subsidiaries because it is management's intent to indefinitely reinvest such earnings. During the 2006 fiscal year, the Company reduced certain intercompany accounts, requiring the utilization of some undistributed earnings of its German subsidiary. The resulting tax was absorbed by the utilization of net operating loss carryforwards.

Going forward, the Company does not intend to record deferred income taxes on future undistributed earnings of its foreign subsidiaries because it is management's intent to indefinitely reinvest such earnings. Upon distribution of these earnings, the Company may be subject to U.S. income taxes and/or foreign withholding taxes.

7. SEVERANCE COSTS

During the year ended September 30, 2006, the Company accrued compensation expense of \$437 for severance costs upon the termination of the Managing Director of the Company's German subsidiary. These costs are a component of general and administrative expenses in the accompanying Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss), and the accrual for these costs is included in Accrued expenses and other current liabilities in the accompanying Condensed Consolidated Balance Sheets. These severance costs are being paid in twelve monthly equal payments during the period from July 1, 2006 through June 30, 2007. As of September 30, 2006 and June 30, 2007, the remaining accrual is \$334 and \$17, respectively.

8. REVOLVING CREDIT ARRANGEMENTS AND SHORT TERM BORROWINGS

Under the terms of revolving credit facilities with two German banks, the Company may borrow up to 1,500 Euros (1,000 Euros and 500 Euros, respectively) or \$2,021 for working capital needs. These renewable credit lines allow the Company to borrow at interest rates ranging from 8.05% to 10.0%. At June 30, 2007, the Company had outstanding borrowings of 851 Euros or \$1,147. At September 30, 2006, the Company had 819 Euros or \$1,039 outstanding borrowings under the revolving credit agreements. The 500 Euro revolving credit facility is secured by accounts receivable of the German subsidiary. The 1,000 Euros revolving credit facility is collateralized by a mortgage on the Company's German facility and a guarantee up to 4,000 Euros or \$5,388 by the Parent Company.

In November 2005, the Company entered into a revolving credit facility in the U.S. for up to \$1,500, expiring on November 18, 2007. At June 30, 2007, the Company had no outstanding borrowings on this credit facility. At September 30, 2006, the Company had \$1,500 outstanding under this revolving credit facility. The U.S. accounts receivable and inventory assets collateralize the borrowing under the revolving credit facility. The Company is required to maintain a maximum senior debt to tangible net worth ratio of 2.0 to 1.0. As of June 30, 2007, the Company was in compliance with this covenant. In addition, the Company maintains a lock box arrangement with the bank.

On June 30, 2006, the Company issued a \$3,000 convertible debenture with detachable warrants to purchase up to 175,000 shares of its common stock. The debenture bears interest at 5.0% per year, was due upon the earlier of August 1, 2007 or upon a change of control of the Company and was convertible into common stock at a price of \$5.15 per share at any time at the election of the holder. The warrants were exercisable at \$5.15 per share at any time at the election of the shareholder until the earlier of the third anniversary of the date of issuance or upon a change in control of the Company. On March 27, 2007, the warrant agreement was amended to provide that the warrant holder has no cash settlement rights under any circumstances. As of June 30, 2007, the holder of the \$3,000 of convertible debentures had converted all of the debentures into 582,524 shares of common stock at the stated conversion price of \$5.15. This transaction has been excluded from the Condensed Consolidated Statement of Cash Flows as it represents a non-cash transaction.

Under the Registration Rights Agreement, which requires common shares to be registered for the convertible debenture and warrants, the Company was required to file a Form S-1 registration statement with the United States Securities and Exchange Commission ("S-1") the earlier of the day following the filing of the Company's 10-K or December 31, 2006. The Company was then required to have the shares registered within 60 days of the filing date of the S-1. In March 2007, the Securities and Exchange Commission approved the registration of the shares.

The relative fair value of the detachable warrants at inception of the convertible debenture agreement was \$275 and was computed using the Black-Scholes pricing model under the following assumptions: (1) expected life of 3 years; (2) volatility of 53.5%, (3) risk free interest of 5.13% and dividend yield of 0%. The proceeds of the convertible debenture were allocated to debt and warrants based on their relative fair values. The relative fair value of the warrants was recorded to additional paid-in capital and resulted in a discount on the convertible debenture, which will be amortized from debt discount to interest expense over the one-year term of the debenture. The remaining unamortized balance of the warrants as of June 30, 2007 is \$0. The convertible debenture balance of \$0 and \$2,793 as of June 30, 2007 and September 30, 2006, respectively, net of debt discount, is included in Short-term borrowings on the accompanying Condensed Consolidated Balance Sheets. In addition, \$357 of direct costs incurred relating to the issuance of the convertible debenture was recorded as debt issuance costs in Other current assets, which was fully amortized to interest expense by June 30, 2007.

9. DERIVATIVE INSTRUMENTS

The Company accounts for its hedging activities in accordance with SFAS No. 133, "Accounting for Derivatives and Hedging Activities" ("SFAS No. 133") as amended. SFAS No. 133 requires that all hedging activities be recognized in the balance sheet as assets or liabilities and be measured at fair value. Gains or losses from the change in fair value of hedging instruments that qualify for hedge accounting are recorded in other comprehensive income. The Company's policy is to specifically identify the assets, liabilities or future commitments being hedged and monitor the hedge to determine if it continues to be effective. The Company does not enter into or hold derivative instruments for trading or speculative purposes. The fair value of the Company's interest rate swap agreement for its 1,500 Euro or \$2,021 long-term loan is based on dealer quotes and was not significant as of June 30, 2007. The loan is due on March 30, 2012 in monthly installments of approximately 63 Euros or \$84 including principal and interest based on an adjustable rate as determined by one-month EURIBOR, fixed by a swap agreement for the life of the loan with the lender at 3.7% as a cash flow hedge. The proceeds were used to construct new facilities.

As indicated in Note 8, on June 30, 2006, the Company issued a \$3,000 convertible debenture which contained features that qualify as embedded derivatives that require bifurcation, however, the value ascribed to these features was determined to be de-minimus to the overall financial statement presentation and accordingly, value was not allocated to these features and the carrying value of the convertible debenture was not reduced. As of June 30, 2007, the \$3,000 convertible debenture had fully converted into common stock.

10. COMMON STOCK

On April 10, 2007, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue to three institutional investors 1,626,012 shares of common stock for gross proceeds of \$12,000. The Company closed this transaction on April 19, 2007 with net proceeds of \$11,494. In connection with the transaction, the Company entered into a Registration Rights Agreement, under which the Company filed a Registration Statement with the Securities and Exchange Commission for the resale of common stock sold in the private placement on June 1, 2007. In June 2007, the Securities and Exchange commission approved the registration of the shares.

11. SEGMENT DATA

The Company operates principally in one industry providing specialty surgical products and tissue processing services. These operations include two geographically determined segments: the United States and International. The Company evaluates performance based on the operating income of each segment. The accounting policies of these segments are consistent with prior periods. The Company accounts for intersegment sales and transfers at contractually agreed-upon prices.

The Company's reportable segments are strategic business units that offer products and services to different geographic markets. They are managed separately because of the differences in these markets as well as their physical location.

A summary of the operations and assets by segment are as follows:

| | Three Months Ended June 30, 2007 | | | Three Months Ended June 30, 2006 | | |
|------------------------------|----------------------------------|---------------|------------|----------------------------------|---------------|------------|
| | International | United States | Total | International | United States | Total |
| Gross revenue | \$ 5,874 | \$ 10,078 | \$ 15,952 | \$ 3,975 | \$ 6,492 | \$ 10,467 |
| Less: Intercompany | (1,789) | - | (1,789) | (467) | - | (467) |
| Total revenue - third party | \$ 4,085 | \$ 10,078 | \$ 14,163 | \$ 3,508 | \$ 6,492 | \$ 10,000 |
| Operating income (loss) | \$ 1,193 | \$ 470 | \$ 1,663 | \$ (919) | \$ (327) | \$ (1,246) |
| Interest expense | \$ 85 | \$ 287 | \$ 372 | \$ 28 | \$ 47 | \$ 75 |
| Income tax expense (benefit) | \$ 429 | \$ (4,945) | \$ (4,516) | \$ (413) | \$ - | \$ (413) |
| Net income (loss) | \$ 687 | \$ 5,220 | \$ 5,907 | \$ (712) | \$ (417) | \$ (1,129) |
| Capital expenditures | \$ 186 | \$ 139 | \$ 325 | \$ 1,759 | \$ 557 | \$ 2,316 |
| Identifiable assets | \$ 19,813 | \$ 39,019 | \$ 58,832 | \$ 18,239 | \$ 18,527 | \$ 36,766 |

| | Nine Months Ended June 30, 2007 | | | Nine Months Ended June 30, 2006 | | |
|------------------------------|---------------------------------|---------------|------------|---------------------------------|---------------|------------|
| | International | United States | Total | International | United States | Total |
| Gross revenue | \$ 16,008 | \$ 27,563 | \$ 43,571 | \$ 11,533 | \$ 17,874 | \$ 29,407 |
| Less: Intercompany | (4,928) | - | (4,928) | (2,258) | - | (2,258) |
| Total revenue - third party | \$ 11,080 | \$ 27,563 | \$ 38,643 | \$ 9,275 | \$ 17,874 | \$ 27,149 |
| Operating income (loss) | \$ 1,727 | \$ 2,020 | \$ 3,747 | \$ (742) | \$ (885) | \$ (1,627) |
| Interest expense (income) | \$ 223 | \$ 793 | \$ 1,016 | \$ 39 | \$ 14 | \$ 53 |
| Income tax expense (benefit) | \$ 589 | \$ (4,945) | \$ (4,356) | \$ (711) | \$ - | \$ (711) |
| Net income (loss) | \$ 928 | \$ 6,269 | \$ 7,197 | \$ (575) | \$ (613) | \$ (1,188) |
| Capital expenditures | \$ 1,309 | \$ 470 | \$ 1,779 | \$ 2,365 | \$ 2,915 | \$ 5,280 |
| Identifiable assets | \$ 19,813 | \$ 39,019 | \$ 58,832 | \$ 18,239 | \$ 18,527 | \$ 36,766 |

12. EARNINGS (LOSS) PER SHARE

The following is a reconciliation of the numerators and denominators of the basic and diluted earnings (loss) per share computations for the three and nine-month periods ended June 30, 2007 and 2006 (in thousands, except share and per share amounts). The Company has excluded 35,000 and 120,000 stock options for the three and nine-month periods ended June 30, 2007, as such stock options are anti-dilutive to the calculation. The Company has excluded 387,960 and 2,485,000 stock options for the three and nine-month periods ended June 30, 2006, respectively, as such shares are anti-dilutive to the calculation.

| | Three Months Ended June 30, | | Nine Months Ended June 30, | |
|-------------------|-----------------------------|------------|----------------------------|------------|
| | 2007 | 2006 | 2007 | 2006 |
| Numerator | | | | |
| Net income (loss) | \$ 5,907 | \$ (1,129) | \$ 7,197 | \$ (1,188) |

| | | | | | |
|-------------------------------------------------------------------------------------------------------|------------|------------|------------|------------|--|
| Denominator | | | | | |
| Weighted-average shares of common stock outstanding used in calculation of basic earnings per share | 18,517,927 | 16,058,724 | 17,201,897 | 15,993,936 | |
| Effect of dilutive securities | | | | | |
| Stock options, warrants and convertible debentures | 1,432,430 | - | 1,528,678 | - | |
| Weighted-average shares of common stock outstanding used in calculation of diluted earnings per share | 19,950,357 | 16,058,724 | 18,730,575 | 15,993,936 | |
| Basic earnings per share | \$ 0.32 | \$ (0.07) | \$ 0.42 | \$ (0.07) | |
| Diluted earnings per share | \$ 0.30 | \$ (0.07) | \$ 0.38 | \$ (0.07) | |

13. LEGAL PROCEEDINGS

The Company is party to various claims, legal actions, complaints and administrative proceedings arising in the ordinary course of business. In management's opinion, the ultimate disposition of these matters will not have a material adverse effect on its financial condition, cash flows or results of operations.

In 2003, the Company received a proposed judgment in Germany as the result of a dispute between the Company and a former international distributor. The estimated settlement, including legal costs was accrued as a litigation contingency. In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company by \$406 between the Company and a former international distributor. At September 30, 2005, the Company maintained an accrual of \$476 with respect to the remaining appeal and legal costs. At September 30, 2006, the Company agreed to a settlement of \$360 resulting from a dispute between the Company and a former international distributor and recorded a change in estimate of approximately \$91 as a reduction of accrued expenses, which reduced the general and administrative expense for the year. In the second quarter of 2007, the remaining accrual of \$25 was reversed.

On October 12, 2005, the Company issued a voluntary recall of all product units which utilized donor tissue received from BioMedical Tissue Services/BioTissue Recovery Services ("BioMedical"). This action was taken because the Company was unable to satisfactorily confirm that BioMedical had properly obtained donor consent. The Company quarantined all BioMedical products in its inventory, having a value of \$1,035 and notified all customers and distributors of record regarding this action. In connection with the recall, the Company wrote off \$174 of inventory during 2005, and \$861 for quarantined inventory at September 30, 2006. Additionally, as of September 30, 2005, the Company had accrued \$250 of related costs in connection with the recall. As of June 30, 2007, the accrual for these costs was \$0, due in part to actual payments made for such costs and in part to an adjustment made by management during the three-months ended March 31, 2006 to reduce the accrual by approximately \$150 as a result of a change in management's estimate of other related costs. The effect of this adjustment was to reduce cost of revenue by approximately \$150.

In January 2006, the Company was named as one of several defendants in a class action suit related to the BioMedical recall. The Company intends to vigorously defend this matter and does not believe that the outcome of this class action will have an adverse material effect on the Company's operations, cash flows, financial position or financial statement disclosures.

14. RELATED PARTY TRANSACTIONS

The Company has an exclusive license and distribution agreement with Zimmer Spine, a wholly owned subsidiary of Zimmer Holdings, Inc., whereby Zimmer Spine has been granted the right to act as the Company's exclusive distributor of bone tissue for spinal applications in the United States.

The Company has also engaged Zimmer Dental, a wholly owned subsidiary of Zimmer Holdings, Inc., to act as an exclusive distributor for the Company's bone tissue for dental applications in the United States and certain international markets. Under this distribution agreement, the Company ships directly to Zimmer Dental's customers.

The following represents a summary of the transactions with Zimmer Spine and Zimmer Dental during the periods:

| | Three Months Ended | | Nine Months Ended | |
|----------------------------------|--------------------|----------|-------------------|----------|
| | June 30, | | June 30, | |
| | 2007 | 2006 | 2007 | 2006 |
| Zimmer Spine - Sales | \$ 1,136 | \$ 617 | \$ 3,722 | \$ 1,416 |
| Zimmer Dental - Commissions Paid | \$ 2,552 | \$ 1,936 | \$ 6,629 | \$ 5,086 |

As of June 30, 2007 and September 30, 2006, the net payable to Zimmer Dental was \$2,261 and \$1,918, respectively. As of June 30, 2007 and September 30, 2006, the receivable from Zimmer Spine was \$67 and \$952, respectively.

Zimmer CEP (formerly Centerpulse) USA Holding Co., a subsidiary of Zimmer Holdings, Inc., is a 28% owner of the Company's outstanding shares of common stock as of June 30, 2007.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (In Thousands)

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

The discussion contained in this report under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), contains forward-looking statements that involve risks and uncertainties. The issuer's actual results could differ significantly from those discussed herein. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in "Business" and "Management's Discussion and Analysis or Results of Operations" as well as those discussed elsewhere in this Report. Statements contained in this Report that are not historical facts are forward-looking statements that are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. A number of important factors could cause the issuer's actual results for 2007 and beyond to differ materially from those expressed in any forward-looking statement made by or on behalf of the issuer.

BUSINESS

During the three-months ended June 30, 2007, the Company generated \$14,163 in revenues, which represented the highest quarterly revenue in the Company's history. The Company continues to experience strong growth in U.S. dental sales. For the three-months ending June 30, 2007, U.S. dental sales totaled \$6,567 up 39% from the same quarter last year. U.S. machined graft spine sales continued to grow during the quarter and the Company continued to grow the hernia market with Davol. Mentor launched breast reconstruction dermis products to clinical sites during the second quarter and subsequently launched the breast reconstruction dermis products nationwide in the U.S. in early July. On May 9, 2007, the Company entered into an agreement with Coloplast Corporation to expand the urology business internationally. For the quarter ended June 30, 2007, Surgical Specialties (includes urology, ophthalmology, hernia, breast reconstruction and ENT) increased 107% over the same period in the prior year. The increase was due primarily to sales of the new hernia repair and breast reconstruction products.

The international operations continue to grow at double-digit growth patterns.

Gross margins continue to improve due to further efficiencies in manufacturing and increased production volumes and the introduction of new products with higher margins.

As a result of increased revenues and improved gross margins, the Company generated net income for the quarter ending June 30, 2007, which represented the fourth consecutive quarterly profit.

In April 2007, the Company entered into a Securities Purchase Agreement whereby the Company issued 1,626,012 shares of common stock for gross proceeds of \$12,000. Net proceeds of \$11,494 will be used to fund working capital and general corporate purposes.

The Company's ability to generate positive operational cash flow is dependent upon increasing revenues supported by increased tissue procurement, controlling costs and the development of additional markets and surgical applications worldwide. While the Company believes that it continues to make progress in these areas, there can be no assurances.

RESULTS OF OPERATIONS**FOR THE THREE AND NINE-MONTHS ENDED JUNE 30, 2007 AND 2006****REVENUE**

An analysis of revenue was as follows:

| | Three Months Ended June 30, | | | Nine Months Ended June 30, | | |
|----------------------------|-----------------------------|------------------|------------|----------------------------|------------------|------------|
| | 2007 | 2006 | Change | 2007 | 2006 | Change |
| Dental | \$ 6,567 | \$ 4,727 | 39% | \$ 18,097 | \$ 12,950 | 40% |
| Spine | 1,136 | 617 | 84% | 3,722 | 1,416 | 163% |
| Surgical Specialties | 2,375 | 1,148 | 107% | 5,744 | 3,508 | 64% |
| Total U.S. | \$ 10,078 | \$ 6,492 | 55% | \$ 27,563 | \$ 17,874 | 54% |
| Germany | \$ 936 | \$ 785 | 19% | \$ 2,730 | \$ 2,360 | 16% |
| France | 384 | 317 | 21% | 1,085 | 1,151 | -6% |
| Rest of World | 2,622 | 2,258 | 16% | 6,846 | 5,363 | 28% |
| Other - Distribution Fees | 143 | 148 | -3% | 419 | 401 | 5% |
| Total International | \$ 4,085 | \$ 3,508 | 16% | \$ 11,080 | \$ 9,275 | 19% |
| Total Consolidated | \$ 14,163 | \$ 10,000 | 42% | \$ 38,643 | \$ 27,149 | 42% |

Revenue for the three and nine-month periods ended June 30, 2007 increased over prior year periods by \$4,163 and \$11,494 or 42%, respectively. U.S. revenues for the three and nine-month periods ended June 30, 2007 increased by \$3,586 (\$6,492 to \$10,078) or 55% and \$9,689 (\$17,874 to \$27,563) or 54%, respectively. The increase in U.S. revenues for both periods was fueled by the continuing increase in the demand for the Company's TUTOPLAST(R) bone products for dental applications sold by Zimmer Dental, the Company's distributor, and increased demand for the Company's new machined graft spinal products and new hernia repair and breast reconstruction products. Spine revenues increased by \$519 (\$617 to \$1,136) during the quarter compared to the same period last year. For the nine-month period ended June 30, 2007, spine revenues increased by \$2,306 (\$1,416 to \$3,722) or 163% compared to same period last year. The increase in sales is primarily due to the introduction of three new machined graft spinal products. Surgical Specialties revenues (primarily urology, ophthalmology, hernia, breast reconstruction and ENT) for the three and nine-month periods ended June 30, 2007 increased by \$1,227 (\$1,148 to \$2,375) or 107% and \$2,236 (\$3,508 to \$5,744) or 64%, respectively, due to the new hernia and breast reconstruction products. International revenues for the three and nine-month periods ended June 30, 2007 increased \$577 (\$3,508 to \$4,085) or 16% and \$1,805 (\$9,275 to \$11,080) or 19%, respectively. The increases are primarily due to increased bovine product sales, dental sales and service processing in Germany and increased sales efforts by several key distributors in various countries. In addition, international revenues received a positive impact during the quarter due to the declining exchange rate of the U.S. dollar against the Euro.

GROSS MARGIN

Gross margins for three and nine-month periods ended June 30, 2007 increased over prior year periods from 48% to 59% and from 54% to 60%, respectively. The higher margins were due to (1) efficiencies obtained from higher sales and increased production volumes; and (2) the introduction of new products with higher margins.

GENERAL AND ADMINISTRATIVE

General and administrative expenses for the three month period decreased over the prior year period by \$260 (\$2,273 to \$2,013) and increased \$686 (\$5,629 to \$6,315) for the nine-month period ended June 30, 2007. The decrease for the three-months ended June 30, 2007 was primarily due to lower accounting and consulting fees. The increase for the nine-months ended June 30, 2007 was primarily due to the following: (1) an increase of \$399 in stock option expenses under the Statement of Financial Accounting Standards No. 123R associated with year end grants to employees and the Board of Directors for performance; (2) an increase of \$479 related to salary adjustments, recruiting and relocation costs necessary to attract and retain management personnel and support overall company growth; (3) an increase of \$103 related to public relation expenses; and (4) an increase of \$170 related to product liability insurance due to increased sales volume. These negative variances were offset by the fact that the nine-month period ended June 20, 2006 included a severance charge of \$437, which was not incurred during the nine-month period ended June 30, 2007. As a percentage of sales, general and administrative expenses declined from 23% to 14 % for the three-months ended June 30, 2007 compared to the same period last year.

DISTRIBUTION AND MARKETING

Distribution and Marketing expenses for the three and nine-month periods ended June 30, 2007 increased over prior year periods by \$852 (\$3,332 to \$4,184) or 26% and \$2,237 (\$9,352 to \$11,589) or 24%, respectively. The increase was primarily due to higher marketing fees earned by Zimmer Dental of \$743 (\$1,936 to \$2,679) for the quarter and \$2,056 (\$5,282 to \$7,338) for the nine-month period ended June 30, 2007. These increases are consistent with the overall increases in dental sales for the above referenced periods. As a percentage of sales, Distribution and Marketing expenses declined from 33% to 30% for the three-months ended June 30, 2007 compared to the same period last year due to increased sales from our non-dental distribution partners.

RESEARCH AND DEVELOPMENT

Research and Development expenses for the three and nine-month periods ended June 30, 2007 increased over prior year periods by \$114 and \$243, respectively. As a percentage of revenues, Research and Development expenses decreased from 5% to 4% for the three months ended June 30, 2007 when compared to 2006.

LITIGATION CONTINGENCY

In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company by \$406 between the Company and a former international distributor. At September 30, 2005, the Company maintained an accrual of \$476 with respect to the remaining appeal and legal costs. At September 30, 2006, the Company agreed to a settlement of \$360 resulting from a dispute between the Company and a former international distributor and recorded a change in estimate of approximately \$91 as a reduction of accrued expenses, which reduced the general and administrative expense for the year. In the second quarter of 2007, the remaining accrual of \$25 was reversed.

INTEREST AND OTHER INCOME

Interest and other income, which represents interest income, increased to \$121 for the three months ended June 30, 2007 compared to \$12 for the prior period. This increase is related to interest income from the \$11,494 in net proceeds from the equity financing completed in April 2007.

INTEREST EXPENSE

Interest expense for the three and nine-month periods ended June 30, 2007 increased over prior year periods by \$297 and \$963, respectively. The increases were primarily due to increased borrowings for capital expenditures related to the facility expansion programs in Florida and Germany and interest expense associated with a \$3,000 convertible debenture issued in June 2006. During the three months ended June 30, 2007, the holders of the \$3,000 convertible debenture fully converted the debenture into common shares. In addition, from the \$11,494 in net proceeds from the equity financing completed in April 2007, the Company paid off the \$1,500 outstanding balance on a line of credit with a U.S. bank. The Company also reduced the outstanding balances on the lines of credit with the German banks from \$1,931 to \$1,147. As a result, going forward, the Company expects a reduction in the total interest expense incurred.

FOREIGN CURRENCY LOSS

The Company had foreign currency exchange losses for the three and nine-month periods ended June 30, 2007 of \$21 and \$83, respectively, due to the declining exchange rate of the U.S. dollar against the Euro.

INCOME TAX EXPENSE

Income tax benefit for the three and nine-month periods ending June 30, 2007 was \$4,516 and \$4,356, respectively, due to a third quarter reversal of our valuation allowance of \$4,953 in the U.S., partially offset by income taxes associated with the profitability of our international division. Income tax benefit for the three and nine-month periods ending June 30, 2006 was \$413 and \$711, respectively, due to losses generated by the international division in 2006.

NET INCOME (LOSS)

Net income for the three-month period ended June 30, 2007, totaled \$5,907, or \$.32 and \$.30 basic and diluted earnings per share, respectively. Excluding the tax benefit of \$4,953, net income for the three-month period ended June 30, 2007, totaled \$954 or \$.05 basic and diluted earnings per share, respectively. Net loss for the three-month period ended June 30, 2006, totaled \$1,129, or \$.07 basic and diluted loss per share, respectively.

Net income for the nine-month period ended June 30, 2007, totaled \$7,197, or \$.42 and \$.38 basic and diluted earnings per share, respectively. Excluding the tax benefit of \$4,953, net income for the nine-month period ended June 30, 2007, totaled \$2,244 or \$.13 and \$.12 basic and diluted earnings per share, respectively. Net loss for the nine-month period ended June 30, 2006, totaled \$1,188, or \$.07 basic and diluted earnings per share.

Excluding the third quarter 2007 tax benefit of \$4,953, the increase in net income of \$2,083 and \$3,432 for the three and nine-month periods, respectively, is directly due to higher revenues and improved gross margins.

ACCOUNTS RECEIVABLE

The accounts receivable balance increased by \$590 from the September 30, 2006 balance of \$6,202 to the June 30, 2007 balance of \$6,792. The increase relates directly to the increased growth in revenues.

INVENTORY

The inventory balance increased by \$5,430 from the September 30, 2006 balance of \$12,678 to the June 30, 2007 balance of \$18,108. The increase was primarily due to higher inventory levels to support additional increased demand for dental products and new products introduced in the spine market and the new markets of hernia repair and breast reconstruction.

CRITICAL ACCOUNTING POLICIES

The Company's significant accounting policies are more fully described in Note 2 to the consolidated financial statements in the annual report for the year ended September 30, 2006. However, certain of the accounting policies are particularly important to the portrayal of the financial position and results of operations and require the application of significant judgment by management; as a result, they are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on historical experience, terms of existing contracts, observance of trends in the industry, information provided by customers and information available from other outside sources, as appropriate. The Company's significant accounting policies include:

SHARE-BASED COMPENSATION. We adopted Statement of Financial Accounting Standards No. 123(R), "*Share-Based Payments*" in the first quarter of fiscal year 2006. SFAS No. 123(R) requires the measurement and recognition of compensation expense for all share-based payment awards including employee stock options based on estimated fair values. Under SFAS No. 123(R), we estimate the value of share-based payments on the date of grant using the Black-Scholes model, which was also used previously for the purpose of providing pro forma financial information as required under SFAS No. 123. The determination of the fair value of, and the timing of expense relating to, share-based payment awards on the date of grant using the Black-Scholes model is affected by our stock price as well as assumptions regarding a number of variables including the expected term of awards, expected stock price volatility and expected forfeitures.

INVENTORIES. Inventories are valued at the lower of cost or market. Work in process and finished goods includes costs attributable to direct labor and overhead. Impairment charges for slow moving, excess and obsolete inventories

are recorded based on historical experience, current product demand including meeting periodically with distributors, regulatory considerations, industry trends, changes and risks and the remaining shelf life. As a result of this analysis, the Company records a writedown to reduce the carrying value of any impaired inventory to its fair value, which becomes its new cost basis. If the actual product life cycles, demand or general market conditions are less favorable than those projected by management, additional inventory impairment charges may be required which would affect future operating results due to increased costs from the resulting adjustment. The adequacy of these impairment charges is evaluated quarterly.

REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE. Revenue on product sales and tissue service processing is recognized when persuasive evidence of an arrangement exists, the price is fixed and final, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Oral or written purchase authorizations are generally obtained from customers for a specified amount of product at a specified price. Revenue from surgical products is recognized upon the shipment of the processed tissues. The Company's terms of sale are FOB shipping point. Title transfers at time of shipment. Customers are provided with a limited right of return. Reasonable and reliable estimates of product returns are made in accordance with SFAS No. 48 and allowances for doubtful accounts are based on significant historical experience. Revenue from distribution fees includes nonrefundable payments received as a result of exclusive distribution agreements between the Company and independent distributors. Distribution fees under these arrangements are recognized as revenue to approximate services provided under the contract. Recognition of revenue commenced over the term of the distribution agreement upon delivery of initial products.

VALUATION OF DEFERRED TAX ASSET. We record valuation allowances to reduce the deferred tax assets to the amounts estimated to be recognized. While we consider taxable income in assessing the need for a valuation allowance, in the event we determine it is more likely than not we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance would be made and income increased in the period of such determination. Likewise, in the event we determine we would not be able to realize all or part of our deferred tax assets in the future, an adjustment would be made to the valuation allowance and charged to income in the period of such determination. At June 30, 2007, the Company recorded a tax benefit of \$4,953 due to the reversal of a previously recorded valuation allowance related to our U.S. operations since we have determined that it is more likely than not that our existing deferred tax assets will be realized.

LIQUIDITY AND CAPITAL RESOURCES

At June 30, 2007 and September 30, 2006, the Company had working capital of \$28,165 and \$8,215, respectively. The increase in working capital is a result of \$11,494 of net proceeds from the equity financing completed in April 2007, the full conversion of the \$3,000 convertible debenture into common stock and the reduction of outstanding balances on the Company's short-term lines of credit.

Cash and cash equivalents increased from \$3,463 at September 30, 2006 to \$11,844 at June 30, 2007, as a direct result of \$11,494 of net proceeds from the equity financing completed in April 2007.

The Company had \$1,169 in cash used by operating activities for the nine-month period ended June 30, 2007 compared to cash flow used in operating activities of \$3,455 for the comparable period last year. The primary reason for the use in cash flow for the nine-months ended June 30, 2007 was an increase in inventory levels to support additional increased demand for dental products and the buildup of new products introduced in the spine market and the new markets of hernia repair and breast reconstruction, offset by net income from operations.

Net cash used in investing activities, representing purchases of capital expenditures, was \$1,779 for the nine-months ended June 30, 2007 and \$5,580 for the comparable prior year period. The purchases represented primarily capital expenditures associated with the new facility expansions for the U.S. and German manufacturing plants that began in early 2006 and was completed in 2007.

Net cash provided by financing activities was \$11,286 for the nine-month period ended June 30, 2007 compared to \$8,695 for the nine-month period ending June 30, 2006. During the nine-month period ended June 30, 2007, the Company completed an equity financing which resulted in \$11,494 in net proceeds. During the nine-month period ended June 30, 2006, the Company received proceeds from long term borrowings to finance the expansion of the U.S. and German manufacturing plants, \$3,000 in proceeds from the issuance of convertible debenture and proceeds from short term borrowings to fund working capital.

Future minimum rental payments required under the Company's operating leases that have initial or remaining non-cancelable lease terms in excess of one year on a fiscal year basis are as follows:

| | | |
|------------------|----|-------|
| 7/1/07 - 9/30/07 | \$ | 648 |
| 2008 | | 1,129 |
| 2009 | | 568 |
| 2010 | | 119 |
| 2011 | | 31 |
| | \$ | 2,495 |

Long-term debt consists of senior debt construction loans and capital leases. Future minimum payments on a fiscal year basis are as follows (1):

| | | |
|-------------------------------|----|-------|
| 7/1/07 - 9/30/07 | \$ | 288 |
| 2008 | | 1,119 |
| 2009 | | 616 |
| 2010 | | 616 |
| 2011 | | 518 |
| Thereafter | | 1,174 |
| | \$ | 4,331 |
| Less current portion | | 1,337 |
| Total future minimum payments | \$ | 2,994 |

(1) does not include interest

The Company maintains current working capital credit lines totaling 1,500 Euros or \$2,000 with two German banks and a \$1,500 credit line with a U.S. bank. At June 30, 2007, the Company had outstanding balances of \$1,147 and \$0 for the working capital lines in Germany and the U.S., respectively. On April 10, 2007, the Company entered into a Securities Purchase Agreement whereby the Company agreed to issue to three institutional investors 1,626,012 shares of common stock for net proceeds of \$11,494. Management believes that the working capital as of June 30, 2007 will be adequate to fund ongoing operations. The Company may seek additional financing to meet the needs of its long-term strategic plan. The Company can provide no assurance that such additional financing will be available, or if available, that such funds will be available on favorable terms. The Company's ability to generate positive operational cash flow is dependent upon increasing processing revenue through increased recoveries by tissue banks in the U.S. and Europe, controlling costs, and the development of additional markets and surgical applications for its products worldwide. While the Company believes that it continues to make progress in these areas, there can be no assurances.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For information regarding the Company's exposure to certain market risks, see the Annual Report on Form 10-K for the year ended September 30, 2006. There have been no significant changes to our market risk exposures.

In the United States and in Germany, the Company is exposed to interest rate risk. Changes in interest rates affect interest income earned on cash and cash equivalents and interest expense on revolving credit arrangements. Except for an interest swap associated with \$2,000 of long term debt over six years starting March 31, 2006, the Company does not enter into derivative transactions related to cash and cash equivalents or debt. Accordingly, we are subject to changes in interest rates. Based on June 30, 2007 cash and cash equivalents and long-term debt, a 1% change in interest rates would have a de-minimus impact on our results of operations.

The value of the U.S. dollar compared to the Euro affects our financial results. Changes in exchange rates may positively or negatively affect revenues, gross margins, operating expenses and net income. The international operation currently transacts business primarily in the Euro. Intercompany transactions translate from the Euro to the U.S. dollar. Based on June 30, 2007 outstanding intercompany balances, a 1% change in currency rates would have a de-minimus impact on our results of operations.

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

As of the end of the period covered by this Form 10-Q, the Company's management, including the Chief Executive Officer and the Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Rule 13a-15 of the Securities Exchange Act of 1934. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired objectives. Based upon that evaluation, the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, concluded that the design and operation of the Company's disclosure controls and procedures provided reasonable assurance that the disclosure controls and procedures are effective to accomplish their objectives.

CHANGES IN CONTROL

There has not been any change in the Company's internal control over financial reporting during the nine-month period ended June 30, 2007 that has materially affected, or is reasonably likely to materially affect, those controls.

PART II. OTHER INFORMATION

**ITEM
1. LEGAL PROCEEDINGS**

Refer to Note 13 of the Unaudited Condensed Consolidated Interim Financial Statements.

**ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS**

None.

**ITEM
3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM
4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS**

None.

**ITEM
5. OTHER INFORMATION**

None.

ITEM 6. EXHIBITS

- | | |
|---------|-------------------------------------------------------------------------------------------------------------------------|
| 31.1*** | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 -- Chief Executive Officer |
| 31.2*** | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 -- Chief Financial Officer |
| 32.1*** | Certifications Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |

*** Filed herewith

SIGNATURES

Registrant has duly caused this report to be signed on its behalf by the Pursuant to the requirements of the Securities and Exchange Act of 1934, the undersigned, thereunto duly authorized.

**TUTOGEN MEDICAL,
INC.**

Date: August 14, 2007

/s/ Guy L. Mayer
Chief Executive Officer

Date: August 14, 2007

/s/ L. Robert Johnston, Jr
Chief Financial Officer
(Principal Financial and
Accounting Officer)